Feld: Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Feld, 60 patient peginterferon lambda early treatment RCT: 75% lower progression [p=0.35] and 66% improved viral clearance [p=0.03] https://c19p.org/feld

copied to clipboard

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Feld et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30566-X (preprint 11/12/2020), NCT04354259 (history)

12 Nov 2020 Source PDF Share Tweet

Small outpatient RCT with 30 peginterferon lambda and 30 control patients, showing improved viral clearance with treatment. Single subcutaneous injection of peginterferon lambda 180μg. NCT04354259 (history).

Important missing comments or errors? Let us know.

risk of hospitalization, no change, RR 1.00, p = 1.00, treatment 1 of 30 (3.3%), control 1 of 30 (3.3%).

risk of ER visit, 75.0% lower, RR 0.25, p = 0.35, treatment 1 of 30 (3.3%), control 4 of 30 (13.3%), NNT 10.0.

risk of no viral clearance, 66.4% lower, RR 0.34, p = 0.03, treatment 6 of 30 (20.0%), control 11 of 30 (36.7%), NNT 6.0, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, adjusted for baseline viral load, day 7.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Feld et al., 12 Nov 2020, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, peer-reviewed, 35 authors, study period 18 May, 2020 - 4 September, 2020, average treatment delay 4.3 days, trial NCT04354259 (history).

All Studies Meta Analysis Submit Updates or Corrections

This Paper Peg.. Lambda All

Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit